Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -74.73% is 70% above its 5-year average of -251.71%, near the high end of its 5-year range (-475.06%–-45.27%).
As of the fiscal period ended Tuesday, June 30, 2026. 71.83% above its 12-month average of -265.31%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -74.73%.
RETURN ON EQUITY (ROE)
-74.73%
RETURN ON EQUITY (ROE) AVG TTM
-265.31%
RETURN ON EQUITY (ROE) AVG 3Y
-309.92%
RETURN ON EQUITY (ROE) AVG 5Y
-251.71%
RETURN ON EQUITY (ROE) AVG 10Y
-177.78%
RETURN ON EQUITY (ROE) AVG 15Y
-164.67%
RETURN ON EQUITY (ROE) AVG 20Y
-141.99%
CURRENT VS TTM AVG
+71.83%
CURRENT VS 3Y AVG
+75.89%
CURRENT VS 5Y AVG
+70.31%
CURRENT VS 10Y AVG
+57.97%
CURRENT VS 15Y AVG
+54.62%
CURRENT VS 20Y AVG
+47.37%
SECTOR MEDIAN · HEALTHCARE
-30.74%
median of 343 covered companies
CURRENT VS SECTOR MEDIAN
-143.11%
vs the sector median at left
Cellectar Biosciences, Inc.
Market Cap
$13.34M
Return on Equity (ROE)
-74.73%
TTM Avg
-265.31%
3Y Avg
-309.92%
5Y Avg
-251.71%
Market Cap
$12.63M
Return on Equity (ROE)
N/A
TTM Avg
-201.97%
3Y Avg
-21.23%
5Y Avg
365.72%
Market Cap
$12.46M
Return on Equity (ROE)
N/A
TTM Avg
-162.71%
3Y Avg
-135.96%
5Y Avg
-98.83%
Market Cap
$14.28M
Return on Equity (ROE)
-69.47%
TTM Avg
-55.64%
3Y Avg
-44.95%
5Y Avg
-41.56%
Market Cap
$11.95M
Return on Equity (ROE)
N/A
TTM Avg
-43.97%
3Y Avg
-160.70%
5Y Avg
-188.29%
Market Cap
$11.42M
Return on Equity (ROE)
-37052.06%
TTM Avg
-237.80%
3Y Avg
-258.91%
5Y Avg
-310.30%
Market Cap
$11.41M
Return on Equity (ROE)
-106.87%
TTM Avg
-250.57%
3Y Avg
-230.96%
5Y Avg
-240.83%
Market Cap
$15.30M
Return on Equity (ROE)
-951.92%
TTM Avg
-161.65%
3Y Avg
-122.41%
5Y Avg
-87.71%
Market Cap
$11.01M
Return on Equity (ROE)
-85.82%
TTM Avg
-222.53%
3Y Avg
-140.00%
5Y Avg
-73.12%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $13.34M | -74.73% | -265.31% | -309.92% | -251.71% |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | N/A | -201.97% | -21.23% | 365.72% |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | N/A | -162.71% | -135.96% | -98.83% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | -69.47% | -55.64% | -44.95% | -41.56% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.95M | N/A | -43.97% | -160.70% | -188.29% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.42M | -37052.06% | -237.80% | -258.91% | -310.30% |
| Biofrontera Inc. (BFRI)vs › | $11.41M | -106.87% | -250.57% | -230.96% | -240.83% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -951.92% | -161.65% | -122.41% | -87.71% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | -85.82% | -222.53% | -140.00% | -73.12% |
| BioVie Inc. (BIVI)vs › | $10.86M | -214.92% | -46.13% | -156.76% | -652.77% |
ROE
-74.7%
ROA
-60.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -74.73% |
| 2026-03-31 | -441.82% |
| 2025-12-31 | -219.69% |
| 2025-09-30 | -200.99% |
| 2025-06-30 | -389.34% |
| 2025-03-31 | -297.37% |
| 2024-12-31 | -311.87% |
| 2024-09-30 | -330.41% |
| 2024-06-30 | -384.82% |
| 2024-03-31 | -448.19% |
| 2023-03-31 | -475.06% |
| 2022-12-31 | -354.40% |
| 2022-09-30 | -214.14% |
| 2022-06-30 | -125.34% |
| 2022-03-31 | -87.86% |
| 2021-12-31 | -73.00% |
| 2021-09-30 | -56.55% |
| 2021-06-30 | -45.27% |
| 2021-03-31 | -35.15% |
| 2020-12-31 | -27.55% |
| 2020-09-30 | -91.59% |
| 2020-06-30 | -74.32% |
| 2020-03-31 | -275.05% |
| 2019-12-31 | -155.56% |
| 2019-09-30 | -118.88% |
| 2019-06-30 | -85.40% |
| 2019-03-31 | -135.93% |
| 2018-12-31 | -99.83% |
| 2018-09-30 | -79.92% |
| 2018-06-30 | -296.28% |
| 2018-03-31 | -189.84% |
| 2017-12-31 | -126.11% |
| 2017-09-30 | -158.95% |
| 2017-06-30 | -100.19% |
| 2017-03-31 | -71.98% |
| 2016-12-31 | -45.65% |
| 2016-09-30 | -34.27% |
| 2016-06-30 | -22.54% |
| 2016-03-31 | -91.95% |
| 2015-12-31 | -333.07% |
| 2015-06-30 | -287.99% |
| 2015-03-31 | -144.60% |
| 2014-12-31 | -67.72% |
| 2014-09-30 | -65.81% |
| 2013-12-31 | -634.41% |
| 2013-09-30 | -203.12% |
| 2013-06-30 | -178.69% |
| 2013-03-31 | -138.76% |
| 2012-12-31 | -86.60% |
| 2012-09-30 | -94.92% |
| 2012-06-30 | -79.60% |
| 2012-03-31 | -116.74% |
| 2011-12-31 | -78.42% |
| 2011-09-30 | -102.89% |
| 2011-06-30 | -65.59% |
| 2010-12-31 | 201.40% |
| 2009-03-31 | -633.16% |
| 2007-09-30 | -143.64% |
| 2007-06-30 | -156.68% |
| 2007-03-31 | -111.87% |
| 2006-12-31 | -78.10% |
| 2006-09-30 | -47.78% |
| 2006-06-30 | -28.00% |
| 2006-03-31 | -22.94% |
| 2005-12-31 | -64.67% |
